Keyphrases
Ofatumumab
100%
Lutetium-177 (177Lu)
100%
Human Lymphoma
100%
Non-Hodgkin Lymphoma
23%
Tumor
15%
Immunoreactivity
15%
Biodistribution
15%
Therapeutic Efficacy
15%
Median Survival
15%
CD20
15%
Raji Cells
15%
Raji
15%
Radiochemical Yield
15%
Human Dosimetry
15%
Injected Activity
15%
In Vitro Characteristics
15%
C57BL
7%
Murine Model
7%
Tumor Cells
7%
Marrow
7%
Tumor Targeting
7%
Cell Tumor
7%
Current Therapies
7%
Weight Gain
7%
Specific Activity
7%
Improved Patient Outcomes
7%
Weight Loss
7%
Tumor Burden
7%
Dosimetry
7%
Lymphoma Cells
7%
Improved Survival
7%
Clinical Translation
7%
Subcutaneous Tumor
7%
Immunodeficient Mice
7%
Diethylenetriaminepentaacetic Acid
7%
Effective Dose
7%
Biodistribution Studies
7%
Bioluminescence
7%
Chelates
7%
Third Generation
7%
Radiochemical Purity
7%
Tumor Therapeutics
7%
Targeting Efficacy
7%
Cell Injection
7%
Anti-CD20
7%
Lymphoma Model
7%
Pharmacology, Toxicology and Pharmaceutical Science
Ofatumumab
100%
Lutetium 177
100%
Neoplasm
53%
Nonhodgkin Lymphoma
23%
Dosimetry
23%
Biodistribution
23%
Combination Therapy
15%
Immunotherapy
7%
CD20 Antibody
7%
Pentetic Acid
7%
C57BL/6N Mouse
7%
Immunology and Microbiology
Ofatumumab
100%
Tumor Cell
16%
CD20
16%
Immunoreactivity
16%
Immunotherapy
8%
Tumor Volume
8%
Lymphoma Cell
8%
CD20 Antibody
8%
C57BL/6N Mouse
8%
Bioluminescence
8%
Biochemistry, Genetics and Molecular Biology
Ofatumumab
100%
Biodistribution
25%
Immunoreactivity
16%
CD20
16%
Tumor Volume
8%
C57BL/6N Mouse
8%
Bioluminescence
8%